Kimberly-Clark to buy embattled Tylenol maker Kenvue in a deal valued at more than $48 billion
Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever while Kimberly-Clark’s stock tumbled.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
